Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).
暂无分享,去创建一个
M. Rezai | P. Fasching | T. Fehm | H. Tesch | S. Loibl | M. Untch | V. Nekljudova | J. Blohmer | G. von Minckwitz | J. Huober | C. Jackisch | C. Schem | C. Hanusch | C. Solbach | B. Gerber | M. Hauschild | H. Eggemann | G. Kunz